Bristol-Myers Squibb: Q4 beats consensus
(CercleFinance.com) - Bristol-Myers Squibb has posted Q4 2019 adjusted EPS that is up 30% at 1.
22 dollar, nearly 25 cents higher than the consensus.
Its revenues increased by a third to more than 7.9 billion dollars over the period, mainly thanks to the acquisition of Celgene, which is completed last November. However, its gross margin fell 3.4 points to 68.6%.
Posting FY 2019 EPS that is up 18% at 4.69 dollars, the pharmaceutical company says that it targets 6-6.20 dollars for 2020 and 7.15-7.45 dollars for 2021.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
22 dollar, nearly 25 cents higher than the consensus.
Its revenues increased by a third to more than 7.9 billion dollars over the period, mainly thanks to the acquisition of Celgene, which is completed last November. However, its gross margin fell 3.4 points to 68.6%.
Posting FY 2019 EPS that is up 18% at 4.69 dollars, the pharmaceutical company says that it targets 6-6.20 dollars for 2020 and 7.15-7.45 dollars for 2021.
Copyright (c) 2020 CercleFinance.com. All rights reserved.